51 related articles for article (PubMed ID: 9816197)
1. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver.
Chazal M; Etienne MC; Renée N; Bourgeon A; Richelme H; Milano G
Clin Cancer Res; 1996 Mar; 2(3):507-10. PubMed ID: 9816197
[TBL] [Abstract][Full Text] [Related]
2. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.
Ridge SA; Sludden J; Brown O; Robertson L; Wei X; Sapone A; Fernandez-Salguero PM; Gonzalez FJ; Vreken P; van Kuilenburg AB; van Gennip AH; McLeod HL
Br J Clin Pharmacol; 1998 Aug; 46(2):151-6. PubMed ID: 9723824
[TBL] [Abstract][Full Text] [Related]
3. DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.
Saif MW; Syrigos K; Mehra R; Mattison LK; Diasio RB
Pak J Med Sci; 2007; 23(6):832-839. PubMed ID: 18846242
[TBL] [Abstract][Full Text] [Related]
4. Implementation of pharmacogenetic testing in oncology:
Wu A; Anderson H; Hughesman C; Young S; Lohrisch C; Ross CJD; Carleton BC
Front Pharmacol; 2023; 14():1257745. PubMed ID: 37745065
[No Abstract] [Full Text] [Related]
5. Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy.
Diasio RB; Offer SM
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804978
[TBL] [Abstract][Full Text] [Related]
6. Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review.
Hagiwara Y; Yamamoto Y; Inagaki Y; Tomisaki R; Tsuji M; Fukuda S; Fukuda S; Onoda T; Suzuki H; Niisato Y; Tange Y; Ikeda N; Yamada K; Kobayashi M; Akutsu D; Yamada T; Moriwaki T; Narasaka T; Suzuki H; Tsuchiya K
Intern Med; 2022 Aug; 61(16):2449-2455. PubMed ID: 35110482
[TBL] [Abstract][Full Text] [Related]
7. Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase.
Kang J; Kim AH; Jeon I; Oh J; Jang IJ; Lee S; Cho JY
Clin Transl Sci; 2022 May; 15(5):1104-1111. PubMed ID: 34863048
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer.
Malier M; Gharzeddine K; Laverriere MH; Marsili S; Thomas F; Decaens T; Roth G; Millet A
Cancer Res; 2021 Dec; 81(23):5963-5976. PubMed ID: 34645611
[TBL] [Abstract][Full Text] [Related]
9. Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?
Knikman JE; Gelderblom H; Beijnen JH; Cats A; Guchelaar HJ; Henricks LM
Clin Pharmacol Ther; 2021 Mar; 109(3):591-604. PubMed ID: 33020924
[TBL] [Abstract][Full Text] [Related]
10. A Genotyping/Phenotyping Approach with Careful Clinical Monitoring to Manage the Fluoropyrimidines-Based Therapy: Clinical Cases and Systematic Review of the Literature.
Conti V; De Bellis E; Manzo V; Sabbatino F; Iannello F; Dal Piaz F; Izzo V; Charlier B; Stefanelli B; Torsiello M; Iannaccone T; Coglianese A; Colucci F; Pepe S; Filippelli A
J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32899374
[TBL] [Abstract][Full Text] [Related]
11. A review on the importance of genotyping and phenotyping in fluoropyrimidine treatment.
Deac AL; Burz CC; Bocşe HF; Bocşan IC; Buzoianu AD
Med Pharm Rep; 2020 Jul; 93(3):223-230. PubMed ID: 32832886
[TBL] [Abstract][Full Text] [Related]
12. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.
García-González X; Kaczmarczyk B; Abarca-Zabalía J; Thomas F; García-Alfonso P; Robles L; Pachón V; Vaz Á; Salvador-Martín S; Sanjurjo-Sáez M; López-Fernández LA
Cancer Chemother Pharmacol; 2020 Jul; 86(1):45-54. PubMed ID: 32529295
[TBL] [Abstract][Full Text] [Related]
13. DPD status and fluoropyrimidines-based treatment: high activity matters too.
Chamorey E; Francois E; Etienne MC; Ferrero JM; Peyrade F; Barranger E; Bozec A; Largillier R; Cassuto O; Viotti J; Schiappa R; Milano G
BMC Cancer; 2020 May; 20(1):436. PubMed ID: 32423482
[TBL] [Abstract][Full Text] [Related]
14. A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer.
Marin C; Krache A; Palmaro C; Lucas M; Hilaire V; Ugdonne R; De Victor B; Quaranta S; Solas C; Lacarelle B; Ciccolini J
Clin Transl Sci; 2020 Jul; 13(4):761-768. PubMed ID: 32058656
[TBL] [Abstract][Full Text] [Related]
15.
Wigle TJ; Tsvetkova EV; Welch SA; Kim RB
Pharmaceutics; 2019 May; 11(5):. PubMed ID: 31052357
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus enterocolitis in a patient with dihydropyrimidine dehydrogenase deficiency after capecitabine treatment: A case report.
Inoue F; Yano T; Nakahara M; Okuda H; Amano H; Yonehara S; Noriyuki T
Int J Surg Case Rep; 2019; 56():55-58. PubMed ID: 30831507
[TBL] [Abstract][Full Text] [Related]
17. Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.
Henricks LM; Jacobs BAW; Meulendijks D; Pluim D; van den Broek D; de Vries N; Rosing H; Beijnen JH; Huitema ADR; Guchelaar HJ; Cats A; Schellens JHM
Br J Clin Pharmacol; 2018 Dec; 84(12):2761-2769. PubMed ID: 30047584
[TBL] [Abstract][Full Text] [Related]
18. Targeting nuclear thymidylate biosynthesis.
Chon J; Stover PJ; Field MS
Mol Aspects Med; 2017 Feb; 53():48-56. PubMed ID: 27876557
[TBL] [Abstract][Full Text] [Related]
19. Association and prediction of severe 5-fluorouracil toxicity with dihydropyrimidine dehydrogenase gene polymorphisms: A meta-analysis.
Leung HW; Chan AL
Biomed Rep; 2015 Nov; 3(6):879-883. PubMed ID: 26623034
[TBL] [Abstract][Full Text] [Related]
20. Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?
Del Re M; Di Paolo A; van Schaik RH; Bocci G; Simi P; Falcone A; Danesi R
EPMA J; 2010 Sep; 1(3):495-502. PubMed ID: 23199091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
